Targeting the SphK1/S1P/S1PR1 axis with specific drugs can reduce tumor progression caused by key proinflammatory cytokines, macrophage infiltration, and obesity (Nagahashi et al., 2018). Here, MBTPS1 is linked to obesity due to melanocortin 4 receptor deficiency.